Skip to main content
About
Management
Board of Directors
Scientific Advisory Board
Business Development
Contact Us
Pipeline
Programs
KRAS G12C Inhibitor (MRTX849)
Sitravatinib (MGCD516)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Careers
Mission & Values
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2020
2019
2018
2017
2016
2015
2014
2013
2/25/2020
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
2/19/2020
Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/15/2020
Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Symposium
1/14/2020
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
1/09/2020
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
1/08/2020
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
1/06/2020
Mirati Therapeutics Announces Executive Management Changes
1/02/2020
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference